The French industrial gas tier one magnate, Air Liquide, has acquired German SME, Licher Medical Therapy (LMT).
Founded in 2000, Licher specifically deals in medico-technical management of Parkinson’s disease and immunodeficiency through infusion therapy. The company turned over €3.7m in 2010 and takes care of over 1,500 patients.
Air Liquide described the deal as necessary to creating a global homecare offering to Parkinson’s patients. It compliments the French tier one’s prior distribution agreement with Britannia, part of the STADA Group. Within the contract, Air Liquide secured German and Austrian distribution rights for apomorphine, brand name APO-go.
According to Air Liquide, home infusion therapy is on the increase with countries such as France and the USA offering growth opportunity. Pascal Vinet, Vice President of Healthcare World Business Line and member of the Group Executive Committee was commented as being ‘delighted’ with the acquisition.
He added, “We are delighted with this acquisition which allows us, beyond France, to become a major operator in Germany in the global home healthcare management of Parkinson’s disease and immunodeficient patients treated with infusion therapy. It demonstrates our development strategy in home healthcare and our commitment in the field of infusion therapy. Health is one of the Group’s growth drivers.”